arag
Small moleculeexperimentalImaging agent
Arag is a small town in Sangli district in the Indian state of Maharashtra. It is approximately 30 km south east of the much larger urban conglomeration of Sangli-Miraj. — Wikipedia
Clinical trial activity
14 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2015 (NCT02323893)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaArag ↗
Also known as
- arag
- arag
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06107374 | Phase 2 | Nov 1, 2023 | CellSight Technologies, Inc., University of Iowa |
| NCT06084806 | Phase 2 | Oct 31, 2023 | CellSight Technologies, Inc., University of Iowa |
| NCT05096234 | Phase 2 | Sep 28, 2021 | CellSight Technologies, Inc., Stanford University |
| NCT04260256 | Phase 2 | Aug 31, 2021 | CellSight Technologies, Inc., Oregon Health and Science University, Stanford University |
| NCT04815096 | Early Phase 1 (Phase 1) | Apr 15, 2021 | CellSight Technologies, Inc., University of California, San Francisco |
| NCT04726215 | Phase 2 | Apr 15, 2021 | CellSight Technologies, Inc. |
| NCT04678440 | Early Phase 1 (Phase 1) | Mar 31, 2021 | CellSight Technologies, Inc., University of California, Davis |
| NCT04524195 | Phase 1 | Feb 1, 2021 | CellSight Technologies, Inc., Johns Hopkins University, Stand Up To Cancer |
| NCT04401995 | Phase 2 | Jun 30, 2020 | CellSight Technologies, Inc., Checkmate Pharmaceuticals, University of Pittsburgh |
| NCT04052412 | Phase 1 | Jul 16, 2019 | CellSight Technologies, Inc., University of Tennessee |
| NCT03684655 | Phase 1 | Sep 21, 2018 | National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco |
| NCT03142204 | Phase 1 | May 1, 2017 | CellSight Technologies, Inc., University of California, San Francisco |
| NCT03007719 | N/A | Mar 7, 2017 | CellSight Technologies, Inc., University of California, San Francisco |
| NCT02323893 | Phase 1 | Feb 1, 2015 | CellSight Technologies, Inc., University of California, San Francisco |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CellSight Technologies, Inc. | For profit | 13 | 7 | 3 | 2015 |
| University of California, San Francisco | Academic/Hospital | 5 | 2 | 2 | 2015 |
| Stanford University | Academic/Hospital | 2 | 1 | 1 | 2021 |
| University of Iowa | Academic/Hospital | 2 | 0 | 1 | 2023 |
| Checkmate Pharmaceuticals | For profit | 1 | 0 | 1 | 2020 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2018 |
| Oregon Health and Science University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Stand Up To Cancer | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of California, Davis | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Tennessee | Academic/Hospital | 1 | 1 | 1 | 2019 |
12 organizations
Page 1 / 1